Novartis Reaches Deal With Watson For Nicotine Replacement Products
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals is expanding the over-the-counter sales base for its smoking cessation line through a partnership with Novartis Consumer Health
You may also be interested in...
Commit Lozenge Generic Equivalent Application Filed
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges
Commit Lozenge Generic Equivalent Application Filed
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges
Commit Lozenge Generic Equivalent Application Filed
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges